Cytomed Therapeutics Ltd is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: every model's value for Cytomed Therapeutics Ltd is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Price vs value
Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.
Cytomed Therapeutics Ltd valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders1 buying, 0 selling5 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds1 adding, 2 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Cytomed Therapeutics Ltd's trailing-twelve-month revenue grew 377.5% year on year, with a free-cash-flow margin of -1336.5%.
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 7.9% while net income fell 61.8%: a 54pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Fast growth. Revenue grew 377.5% over the last 12 months.
- Net cash. Cash exceeds long-term debt by $0.0bn.
Things to watch
- Burning cash. Free cash flow was -1336.5% of revenue over the last 12 months.
- Heavy stock-based pay. Stock pay equals 214.0% of revenue: a real cost that cash-flow figures leave out.
Price chart
- 1 day-5.5%
- 1 week-3.4%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- Revenue (TTM)
- $248,384
- Net margin
- -1227.1%
- EPS (TTM, diluted)
- $-0.26
Growth
- Revenue growth
- +377.5%
- Share count change
- +0.9%
Cash
- Free cash flow (TTM)
- -$3.3M
- FCF margin
- -1336.5%
- Stock pay % of revenue
- 214.0%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for GDTC from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Cytomed Therapeutics Ltd as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$0.0 ~$0.1–$0.2 | Left out: out of range vs price (0.03x) |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cytomed Therapeutics Ltd with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Cytomed Therapeutics Ltd: too few analysts cover it.
Positioning
- Short interest
- 0.5% of tradable shares
- Days to cover
- 0.93 at average volume
- Short interest, 1 month
- +435% to October 15, 2026
- Held by institutions
- 0% of shares
- Held by insiders
- 70.5% of shares
- Employees
- 42 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial statements
| Fiscal year | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|
| Income | ||
| Revenue | 52 | 248 |
| Net income | −1,884 | −3,048 |
| Diluted EPS | −$0.16 | −$0.26 |
| Growth (year on year) | ||
| Revenue | — | +377.5% |
| Margins | ||
| Net margin | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% |
| Cash flow | ||
| Cash from operations | −2,028 | −2,831 |
| Capital spending | 1,048 | 488 |
| Free cash flow | −3,076 | −3,320 |
| Stock-based pay | — | 532 |
| Free cash flow after stock pay | — | −3,851 |
| Balance sheet | ||
| Cash | 3,438 | 1,630 |
| Total debt | 316 | 318 |
| Net debt (negative = net cash) | −3,122 | −1,311 |
| Diluted shares | 12m | 12m |
Financial health
- Short-term assets cover short-term liabilities $3m of assets due within a year against $551,496 of liabilities due within a year.
- Short-term assets cover long-term liabilities $3m short-term assets against $328,266 of longer-dated liabilities.
- More cash than debt $2m of cash against $318,456 of debt.
- Debt below 40% of shareholders' equity Debt is 6% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$3m of operating cash flow against $318,456 of debt.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +0.9%
- year over year
- R&D spending
- 683.6%
- of revenue
- Days sales outstanding
- 1791 days
- receivables vs revenue
Competitors: side by side with peers
| Last 12 months unless stated | GDTC | CLNN | CRVO | CLDX | CRDF | IBIO | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $248384 | $197000 | $331295 | $158000 | $508000 | $100000 | $55m |
| Revenue growth, last 12 months | 377.5% | −31.1% | −95.7% | −97.3% | −7.0% | −75.0% | 12.7% |
| Revenue growth, 3-year average | — | −36.9% | −52.7% | −63.5% | 7.2% | −62.4% | 13.7% |
| Revenue growth, latest quarter | — | 233.3% | −100.0% | −97.0% | −14.0% | −100.0% | 10.2% |
| Gross margin | — | 70.1% | 100.0% | — | 100.0% | 59.9% | 82.9% |
| Operating margin | — | <−999% | <−999% | <−999% | <−999% | <−999% | −189.4% |
| Operating margin, 3-year average | — | <−999% | <−999% | <−999% | <−999% | <−999% | −363.5% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −172.8% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −168.8% |
| Free-cash-flow margin | <−999% | <−999% | — | <−999% | <−999% | <−999% | −168.1% |
| Free-cash-flow margin, 3-year average | — | <−999% | — | <−999% | <−999% | <−999% | −310.0% |
| Stock pay / revenue | 214.0% | >999% | 393.0% | >999% | >999% | >999% | 20.7% |
| Change in share count | 0.9% | 35.4% | 8.4% | 4.7% | 15.8% | 13.9% | 8.1% |
Who owns it
Funds buying and selling- Reported value
- $12,240
- Institutions reporting
- 3
- Shares held vs prior quarter
- ▼ 27.3%
- Positions opened / closed
- 1 / 1
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Axiom Investment Management LLC | $7,243 | 7K | 59.2% | New |
| UBS Group AG | $4,976 | 5K | 40.7% | ▼ 21.9% |
| Osaic Holdings, Inc. | $21 | 0K | 0.2% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cytomed Therapeutics Ltd's complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Choo Chee Kong Director | July 20, 2026 | Buy | 100,000 | $1.50 | $150,000 |
| Choo Chee Kong Director | July 20, 2026 | Buy | 100,000 | $1.50 | $150,000 |
| Choo Chee Kong Director | July 14, 2026 | Buy | 100,000 | $1.50 | $150,000 |
| Choo Chee Kong Director | July 14, 2026 | Buy | 100,000 | $1.50 | $150,000 |
| Choo Chee Kong Director | May 13, 2026 | Buy | 112,000 | $1.15 | $128,800 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Cytomed Therapeutics Ltd in brief
- What does Cytomed Therapeutics Ltd do?
- Cytomed Therapeutics Ltd is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Cytomed Therapeutics Ltd's stock ticker?
- Cytomed Therapeutics Ltd trades under the ticker GDTC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- What is Cytomed Therapeutics Ltd's revenue, and how fast is it growing?
- Over its most recent trailing twelve months, Cytomed Therapeutics Ltd reported revenue of $248,384, 377.5% higher than a year earlier, according to its SEC filings.
- What is Cytomed Therapeutics Ltd's free cash flow?
- Cytomed Therapeutics Ltd's free-cash-flow margin is -1336.5% of revenue over the trailing twelve months.
- Who are Cytomed Therapeutics Ltd's largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Axiom Investment Management LLC, UBS Group AG and Osaic Holdings, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- How much debt does Cytomed Therapeutics Ltd have?
- Cytomed Therapeutics Ltd's debt-to-equity ratio is 6.3%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
- Who are Cytomed Therapeutics Ltd's competitors?
- In our Biotechnology peer group, the companies closest to Cytomed Therapeutics Ltd are Clene Inc., Cervomed Inc., Celldex Therapeutics, Inc., Cardiff Oncology, Inc. and Ibio, Inc. The side-by-side comparison below sets their revenue, margins and growth against Cytomed Therapeutics Ltd's.
- Are insiders buying or selling Cytomed Therapeutics Ltd stock?
- Over the last 12 months, Cytomed Therapeutics Ltd's directors and officers reported 5 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
Follow research on Cytomed Therapeutics Ltd
New research on the companies we cover arrives in the weekly email. Free, one email a week.